Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc. (Vor Bio) (Nasdaq: VOR) is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases through the development of telitacicept, a dual BAFF/APRIL fusion protein. The VOR news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow how Vor Bio’s telitacicept program and corporate strategy evolve over time.
According to recent announcements, Vor Bio’s news flow centers on late-stage clinical data for telitacicept in B‑cell–mediated autoimmune diseases, including generalized myasthenia gravis, Sjögren’s disease, systemic lupus erythematosus, and IgA nephropathy. The company and its collaborator RemeGen Co., Ltd. have reported Phase 3 results from studies conducted in China, including data presented at major medical meetings and in peer‑reviewed publications. These updates highlight efficacy endpoints, durability of response, and safety findings for telitacicept across multiple indications.
Investors following VOR news can also track capital markets activity, such as underwritten public offerings, private placements with institutional healthcare investors, and at‑the‑market equity sales programs disclosed in company press releases and Form 8‑K filings. Additional news items cover leadership and governance changes, including appointments to the Board of Directors and executive team roles like Chief Medical Officer, Chief Development Officer, and Chief Commercial Officer, which Vor Bio links to its late-stage development and potential commercialization plans.
Vor Bio’s participation in healthcare and investor conferences, including events such as the J.P. Morgan Healthcare Conference and other sector-focused meetings, is another recurring news theme. Visitors to this page can review updates on upcoming presentations, webcasts, and corporate slide decks referenced in SEC filings. For anyone monitoring VOR, the news feed offers a centralized view of clinical milestones, financing decisions, and strategic developments related to telitacicept and Vor Bio’s broader autoimmune disease focus.
Vor Bio (NASDAQ: VOR) reported Q4 and full-year 2025 results and a corporate update. Key highlights: first patient dosed in global Phase 3 UPSTREAM SjD; $75.0 million private placement with TCGX on March 27, 2026; pro-forma cash and investments of $530.2 million as of Dec 31, 2025, projected to fund operations into early 2029. Vor expects topline gMG data in 1H 2027. 2025 R&D was $321.5M (up $228.2M YoY); 2025 G&A was $50.1M. Q4 2025 net income was $1,722.8M driven by warrant fair-value gains; full-year 2025 net loss was $696.0M.
Vor Bio (Nasdaq: VOR) announced dosing of the first patient in UPSTREAM SjD, a global Phase 3, randomized, double-blind, placebo-controlled trial of telitacicept for adult primary Sjögren’s disease.
The trial will enroll ~250 patients, use subcutaneous dosing, and has a primary endpoint of change in ESSDAI at Week 48. Prior Phase 3 data from late 2025 in China showed statistically significant improvements in ESSDAI and ESSPRI.
Vor Bio (Nasdaq: VOR) entered a securities purchase agreement to sell 5,338,078 shares at $14.05 per share in a private placement led by new investor TCGX, expected to raise approximately $75 million before fees. Closing is expected on or about March 30, 2026, subject to customary conditions.
Vor Bio intends to use net proceeds to advance global Phase 3 trials for telitacicept in myasthenia gravis and primary Sjögren’s disease, for business development, and for working capital; registration rights were granted for resale of the shares.
Vor Bio (Nasdaq: VOR) announced inducement grants on November 2025 and March 23, 2026, to eight newly hired employees under its 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The Compensation Committee granted stock options to purchase an aggregate of 215,700 shares and 46,235 RSUs. Options carry ten-year terms with exercise prices of $7.95 to $24.11, equal to closing prices on grant dates. Options vest over four years (25% after 12 months, then monthly for 36 months); RSUs vest over four years (25% after 12 months, then quarterly for 36 months).
Vor Bio (Nasdaq: VOR) will present and hold 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston.
The company presentation is scheduled for Monday, March 2, 2026, 9:50–10:20 AM ET. A live webcast and archived replay will be available for 90 days on the company website.
Vor Bio (Nasdaq: VOR) will present and host one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for Tuesday, January 13, 2026, 10:30 AM–11:10 AM PT at The Westin St. Francis, Georgian Room. A live webcast and archived replay will be available on the company website at https://ir.vorbio.com/events-presentations/. The company is clinical-stage and focuses on autoimmune disease treatments.
Vor Biopharma (Nasdaq: VOR) announced the appointment of Andrew Levin, M.D., Ph.D. of RA Capital and Wouter Joustra of Forbion to its Board of Directors on December 23, 2025.
The appointments follow a $150M PIPE financing that included participation from both investors. Vor Bio said the new directors will support advancement of telitacicept through global Phase 3 programs and contribute to financing and governance strategy. Dr. Levin replaces Sarah Reed, who resigned from the Board. Both appointees are described as having deep life‑sciences investment and late‑stage biotech experience.
Vor Bio (Nasdaq: VOR) entered a securities purchase agreement to sell 13,876,032 shares of common stock at $10.81 per share, expecting gross proceeds of approximately $150 million before expenses. The private placement is expected to close on or about December 18, 2025, subject to customary conditions, and no placement agent was engaged.
Investors include RA Capital, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital, and Venrock Healthcare Capital Partners; Forbion receives the right to appoint one director. Vor Bio plans to use net proceeds to advance development of telitacicept, including a global Phase 3 trial for myasthenia gravis and initiation of a global Phase 3 trial in primary Sjögren's disease, plus working capital. Registration rights will be filed with the SEC for resale of the placement shares.
Vor Bio (NASDAQ: VOR) reported Q3 2025 results and a broad clinical and corporate update on November 13, 2025. Multiple Phase 3 readouts for telitacicept showed positive efficacy and favorable safety across indications: gMG (96.2% ≥3‑point MG‑ADL response at 48 weeks), Sjögren’s disease (placebo‑adjusted ESSDAI −3.8; 71.8% vs 19.3% ≥3‑point ESSDAI at 24 weeks), SLE (67.1% vs 32.7% modified SRI‑4 at Week 52), and IgA nephropathy (55% reduction in 24h‑UPCR at 39 weeks). Corporate: raised expected gross proceeds of $115 million in Nov 2025 offering; cash and marketable securities were $170.5M as of Sept 30, 2025, projected to fund operations into Q2 2027.
Q3 financials show a net loss of $812.7M driven by a loss on warrant liabilities and total liabilities of $2.402B.
Vor Bio (Nasdaq: VOR) priced an underwritten public offering of 10,000,000 common shares at $10.00 per share, generating expected gross proceeds of $100 million before underwriting discounts, commissions and offering expenses. The offering is expected to close on or about November 12, 2025. Vor Bio granted underwriters a 30-day option to purchase up to an additional 1,500,000 shares at the public offering price, less underwriting discounts and commissions. All shares are being sold by Vor Bio pursuant to a shelf registration declared effective by the SEC on March 31, 2025. Final prospectus supplement will be filed with the SEC and copies will be available from the listed underwriters.